NextGen Jane

NextGen Jane is building a large-scale, longitudinal research platform centered on the 'menstrualome'—the molecular data contained in menstrual blood. The company recruits a community of menstruators to mail in used tampons via a patented collection kit, combining these samples with survey data to develop non-invasive diagnostics for conditions like endometriosis and to establish baseline menstrual health. Founded in 2015, the private company is pre-revenue and focused on clinical study recruitment and data generation to validate its platform and future diagnostic products.

Patented at-home tampon collection kit for non-invasive sampling of menstrual blood and endometrial tissue, integrated with longitudinal participant survey data, for genomic and molecular analysis (the 'menstrualome').

NextGen Jane is a pioneer in the specific niche of menstrual blood-based diagnostics. It faces competition from companies developing non-invasive diagnostics for similar indications using different biospecimens (e.g., blood, saliva) or digital symptom tracking tools. Larger diagnostic firms like Roche or Quest could enter the space if the market validates.